Clinical Trials Browser

Phase 1 × Completed × navitoclax × Clear all

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

29 enrolled

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

NCT02520778 2024-08-21

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Completed

27 enrolled

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Phase 1 Completed

12 enrolled

Other solid neoplasm

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Phase 1 Completed

46 enrolled

Other solid neoplasm

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase 1 Completed

19 enrolled

Other solid neoplasm

Solid Tumors

NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Phase 1 Completed

37 enrolled

Other solid neoplasm

Lymphoid Malignancy

NCT01121133 2017-11-21

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1 Completed

12 enrolled

Lymphoid

Lymphoma

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Phase 1 Completed

51 enrolled

Other solid neoplasm

Solid Tumors

NCT00868413 2013-06-07

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Completed

32 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00888108 2012-05-22

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Phase 1 Completed

41 enrolled

Other solid neoplasm

Solid Tumor

NCT01021358 2010-12-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Phase 1 Completed

12 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00743028 2010-10-07

Assess the Oral Bioavailability of New ABT-263 Formulations

Phase 1 Completed

36 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Assess the Oral Bioavailability of New ABT-263 Formulations